Marathon Pharmaceuticals, LLC
1033 Skokie Boulevard
Northbrook
Illinois
60062
United States
Website: http://marathonpharma.com/
Email: info@marathonpharma.com
31 articles about Marathon Pharmaceuticals, LLC
-
Catalyst Pharmaceuticals Expands Commercial Leadership Team
8/6/2018
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced the appointment of several key members to its commercial leadership team.
-
New FDA Head Lifts Hiring Freeze, Takes Aim at the Next Martin Shkreli and Marathon Pharma
5/30/2017
-
Embattled Marathon Pharma May Shutter Operations by May 1
4/26/2017
-
PTC Therapeutics Buys Marathon Pharma's Controversial $89,000-Per-Year DMD Drug for $190 Million
3/16/2017
-
Lawmakers Question the FDA's "Unusual" Approval of Marathon Pharma's Controversial Old DMD Drug
3/16/2017
-
More Senators Demand Answers From Marathon Pharma's CEO And His Pricey DMD Drug
3/6/2017
-
Sarepta Under Pressure As Marathon Pharma Emflaza's Wins FDA Approval for DMD
2/13/2017
-
Marathon Pharma's Drug Pricing Is Playing With Fire
2/13/2017
-
CureDuchenne Applauds The FDA Approval Of Marathon Pharma’s EMFLAZA (deflazacort) For The Treatment Of Duchenne Muscular Dystrophy
2/10/2017
-
Marathon Pharma And Italfarmaco Join cTAP: Learning From Patient Data To Enhance Clinical Trial Design For Duchenne Muscular Dystrophy
2/7/2017
-
Marathon Pharma Appoints New Members To Its Advisory Board
12/21/2016
-
Marathon Pharma Announces Neurology Publication Of Pivotal Phase III Data For Deflazacort For Duchenne Muscular Dystrophy
8/30/2016
-
FDA Accepts Marathon Pharma’ New Drug Applications For Deflazacort For The Treatment Of Duchenne Muscular Dystrophy And Grants Priority Review
8/10/2016
-
Marathon Pharma Names Two New Executive Team Members
7/28/2016
-
Parent Project Muscular Dystrophy Receives Grant From Marathon Pharma To Help Support Acclaimed Certified Duchenne Care Center Program
6/28/2016
-
Marathon Pharma Announces Submission Of Deflazacort New Drug Application To The FDA
6/14/2016
-
Marathon Pharma Presents Analyses At American Academy of Neurology Of A Phase III Clinical Study Of Deflazacort In Patients With Duchenne Muscular Dystrophy (DMD)
4/19/2016
-
Marathon Pharma Announces Nationwide Expanded Access Program For Patients With Duchenne Muscular Dystrophy (DMD)
3/9/2016
-
Marathon Pharma Launches An Expanded Access Program To Provide Deflazacort To U.S. Patients With Duchenne Muscular Dystrophy
12/1/2015
-
Marathon Pharmaceuticals, LLC Receives Rare Pediatric Disease Designation From FDA For Deflazacort As A Potential Treatment Of Duchenne Muscular Dystrophy
10/7/2015